EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rapid and robust immune response boosting with potent, next-generation adjuvant in viral vector-primed primates

Hannah A D King, Caroline Subra iD, Emily Tourtellott, Isabella Swafford, Shraddha Basu, Matthew Rossman, Lana Phillips, Nyerhovwo Obarorakpor, Shilei Ding, Maria Grazia Ferrari, Zoltan Beck, Eric Lewitus und 17 weitere

Journal of Virology · 18.08.2026 · 100 (8)

DOI: 10.1128/jvi.00389-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, erschienen am 18.08.2026. Verfasst von Hannah A D King und 28 weiteren Autor:innen. Beteiligte Einrichtung: U.S. Military HIV Research Program, Center for Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA. Hauptthemen laut MEDLINE: Adjuvants, Immunologic, AIDS Vaccines, HIV-1, HIV Infections. Die Arbeit nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To identify strategies for augmenting vaccine immunogenicity, we compared a pox-protein prime-boost regimen comprising recombinant modified vaccinia virus Ankara and multimeric HIV-1 Env gp145, adjuvanted with Army Liposomal Formulation (ALF) either adsorbed to aluminum salt (ALFA) or formulated with the QS-21 saponin (ALFQ), in rhesus macaques. ALFQ promoted greater magnitude and more durable humoral and cellular immune responses than ALFA, which exhibits similar immunogenicity to aluminum-based adjuvants. Peak Env-specific CD4 + T cell responses assessed by intracellular cytokine staining were 10-fold greater with ALFQ, and CD8 + T cell responses were unexpectedly robust, averaging greater than 1%. ALFQ induced higher levels of several immunostimulatory cytokines in plasma, which correlated with adaptive immune responses. However, vaccination did not protect against heterologous intrarectal challenge with transmitted/founder SHIV-CH505. We provide evidence that CH505 Env may maintain a relatively closed conformation, rendering it less susceptible to targeting by Fc-mediated antibody functions. Overall, ALFQ is a promising adjuvant to improve antibody and T cell response magnitude. IMPORTANCE An effective and durable vaccine preventing HIV-1 acquisition is urgently needed to end the HIV-1 pandemic. To date, of the nine vaccine efficacy trials conducted in humans, only the RV144 vaccine trial demonstrated efficacy in reducing infections, although immune responses waned rapidly. We evaluated a modified HIV-1 vaccine regimen incorporating next-generation adjuvants to improve immune responses and vaccine efficacy in a gold standard, pre-clinical primate model. Adjuvanted protein boosting markedly increased antibody, T cell, and pro-inflammatory response magnitude. These data, combined with the adjuvant’s strong safety and immunogenicity track record in clinical trials, indicate that novel adjuvants represent a promising strategy for improving immune responses to protein immunogens. Future vaccine regimens against HIV-1 and other pathogens for which eliciting robust immunity has been difficult may benefit from incorporating these or related next-generation adjuvants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adjuvants, ImmunologicAIDS VaccinesHIV-1HIV InfectionsAdjuvants, VaccineAnimalsMacaca mulattaImmunization, SecondaryVaccinia virusCD8-Positive T-LymphocytesSaponinsCD4-Positive T-LymphocytesHIV Antibodiesenv Gene Products, Human Immunodeficiency VirusImmunity, CellularCytokinesGenetic VectorsSimian Immunodeficiency VirusAntibodies, NeutralizingLiposomes

Stichwörter der Autor:innen

ALFAALFQ adjuvantsCD8+ T cell responseHIV-1 vaccineSHIV challengeimmune response boostingnext-generation liposomal adjuvantpox viral vectorrhesus macaque

Substanzen

Adjuvants, ImmunologicAIDS VaccinesSaponinssaponin QA-21V1HIV Antibodiesenv Gene Products, Human Immunodeficiency VirusCytokinesAdjuvants, VaccineAntibodies, NeutralizingLiposomes

Autor:innen und Institutionen

  • U.S. Military HIV Research Program, Center for Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
  • Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA.
  • Vaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
  • Centre de Recherche du CHUM, Montreal, Quebec, Canada.
  • Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, Quebec, Canada.
  • BIOQUAL, Inc., Rockville, Maryland, USA.

ORCID-Profile: Caroline Subra, Georgia D Tomaras, Andrés Finzi, Gary R Matyas, Shelly J Krebs, Morgane Rolland, Diane L Bolton

Förderung

  • NIAID NIH HHS

Zitieren

APA

King, H. A. D., Subra, C., Tourtellott, E., Swafford, I., Basu, S., Rossman, M., Phillips, L., Obarorakpor, N., Ding, S., Ferrari, M. G., Beck, Z., Lewitus, E., Bai, H., Dong, M., Slike, B. M., Kim, D., Dussupt, V., Mendez-Rivera, L., Eisel, N., …, & Bolton, D. L. (2026). Rapid and robust immune response boosting with potent, next-generation adjuvant in viral vector-primed primates. Journal of Virology, 100(8). https://doi.org/10.1128/jvi.00389-26

Vancouver

King HAD, Subra C, Tourtellott E, Swafford I, Basu S, Rossman M, et al. Rapid and robust immune response boosting with potent, next-generation adjuvant in viral vector-primed primates. Journal of Virology. 2026;100(8). doi:10.1128/jvi.00389-26

BibTeX
@article{King2026,
  author = {King, Hannah A D and Subra, Caroline and Tourtellott, Emily and Swafford, Isabella and Basu, Shraddha and Rossman, Matthew and Phillips, Lana and Obarorakpor, Nyerhovwo and Ding, Shilei and Ferrari, Maria Grazia and Beck, Zoltan and Lewitus, Eric and Bai, Hongjun and Dong, Ming and Slike, Bonnie M and Kim, Dohoon and Dussupt, Vincent and Mendez-Rivera, Letzibeth and Eisel, Nathan and Zhang, Lu and Williams, LaTonya D and Tomaras, Georgia D and Finzi, Andrés and Matyas, Gary R and Krebs, Shelly J and Rolland, Morgane and Rao, Mangala and Paquin-Proulx, Dominic and Bolton, Diane L},
  title = {Rapid and robust immune response boosting with potent, next-generation adjuvant in viral vector-primed primates},
  journal = {Journal of Virology},
  year = {2026},
  volume = {100},
  number = {8},
  doi = {10.1128/jvi.00389-26}
}
Kostenlos starten →